Completed PHASE4 INTERVENTIONAL 2-arm NCT00589732

Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent (VAL-SUPPRES)

Valsartan for SUPpression of Plaque Volume and Restenosis After Drug-Eluting Stent (The VAL-SUPPRESS TRial)

Sponsor: Novartis

Interventions Valsartan

Updated 6 times since 2017 Last updated: Aug 7, 2012 Started: Sep 30, 2006 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Coronary Artery Disease, this trial is completed. The trial is conducted by Novartis and has accumulated 6 data snapshots since 2006. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Seung-Jung Park

Data source: CardioVascular Research Foundation, Korea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea
• Suwon, South Korea